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Objectives The purpose of this study was to evaluate the association between inflammation and heart failure (HF) risk in older adults.
Background Inflammation is associated with HF risk factors and also directly affects myocardial function.
Methods The association of baseline serum concentrations of interleukin (IL)-6, tumor necrosis factor-, and C-reactive protein
(CRP) with incident HF was assessed with Cox models among 2,610 older persons without prevalent HF enrolled in
the Health ABC (Health, Aging, and Body Composition) study (age 73.6  2.9 years; 48.3% men; 59.6% white).
Results During follow-up (median 9.4 years), HF developed in 311 (11.9%) participants. In models controlling for clinical char-
acteristics, ankle-arm index, and incident coronary heart disease, doubling of IL-6, tumor necrosis factor-, and CRP
concentrations was associated with 29% (95% confidence interval: 13% to 47%; p  0.001), 46% (95% confidence
interval: 17% to 84%; p  0.001), and 9% (95% confidence interval: 1% to 24%; p  0.087) increase in HF risk,
respectively. In models including all 3 markers, IL-6, and tumor necrosis factor-, but not CRP, remained significant.
These associations were similar across sex and race and persisted in models accounting for death as a competing
event. Post-HF ejection fraction was available in 239 (76.8%) cases; inflammatory markers had stronger association
with HF with preserved ejection fraction. Repeat IL-6 and CRP determinations at 1-year follow-up did not provide in-
cremental information. Addition of IL-6 to the clinical Health ABC HF model improved model discrimination (C index
from 0.717 to 0.734; p  0.001) and fit (decreased Bayes information criterion by 17.8; p  0.001).
Conclusions Inflammatory markers are associated with HF risk among older adults and may improve HF risk stratification.
(J Am Coll Cardiol 2010;55:2129–37) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.045e
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009, accepted December 16, 2009.levated in patients with heart failure (HF) and are associ-
ted with outcomes regardless of etiology (1– 6).
See page 2138
nflammatory markers are also elevated in individuals with
symptomatic left ventricular systolic and diastolic dysfunc-
ion (7–9), and experimental studies have suggested that
L-6 and TNF- are associated with left ventricular remod-
ling, fetal gene expression, myocyte hypertrophy, and
yocyte apoptosis (10). These observations raise the possi-
ility that inflammation may be related to a heightened risk
f HF, and previous studies have indeed suggested such an
ssociation (11–13). However, the number of incident HF
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precluding an opportunity to assess
for possible differential association
across major demographic groups
and adequately control for impor-
tant predictors of HF including
incident coronary events. Finally,
the incremental value of inflam-
matory markers for HF risk deter-
mination was not assessed in these
studies.
We recently developed and
validated a prediction model for
incident HF in the elderly, the
Health ABC HF model (14),
based on 9 routinely available
ariables including age, history of coronary heart disease
CHD), electrocardiographic left ventricular hypertrophy,
moking, systolic blood pressure, heart rate, and serum
oncentrations of fasting glucose, creatinine, and albumin.
ost of these risk factors have been associated with inflam-
ation. For example, the association of inflammation with
HD and subclinical atherosclerosis is well documented
15,16), as is the association between inflammation and
iabetes mellitus (17). Systemic low-grade inflammation
as been reported in smokers (18). Both inflammation and
xidative stress have been correlated with chronic kidney
isease (19). Similar associations have been reported for
ypertension and hypoalbuminemia (20,21). Thus, beyond
he direct effects on myocardial cells, inflammation may also
rive HF risk through the creation of a biological milieu
hat predisposes individuals to HF.
In this study, we assessed the association between base-
ine levels of inflammatory markers and risk of HF among
he elderly participants of the Health ABC (Health, Aging,
nd Body Composition) Study in the total cohort and in
redefined subgroups of interest, as well as the possible
ncremental value of these markers for incident HF predic-
ion. In addition, we assessed the impact of multiple
nflammatory marker elevation and the incremental value of
erial biomarker measurements for incident HF prediction.
ethods
tudy population. The study population for this investi-
ation included participants in the Health ABC Study, a
opulation-based cohort of 3,075 community-dwelling men
nd women age 70 to 79 years at inception. To be eligible,
articipants had to report no difficulty in walking 1⁄4 mile or
limbing 10 stairs without resting. Participants were iden-
ified from a random sample of white Medicare beneficiaries
nd all age-eligible black community residents in designated
ip code areas surrounding Pittsburgh and Memphis. Ex-
lusion criteria included difficulties with activities of daily
iving, obvious cognitive impairment, inability to commu-
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CRP  C-reactive protein
EF  ejection fraction
HF  heart failure
HR  hazard ratio
IL  interleukin
IQR  interquartile range
TNF  tumor necrosis
factoricate with the interviewer, and intention of moving within ayears. All participants gave written informed consent; the
nstitutional review boards at both study sites approved the
rotocol. Baseline data were collected from 1997 to 1998,
nd these results represent the outcomes during 10 years of
ollow-up. The presence of cardiovascular disease at baseline
as based on International Classification of Disease, Ninth
dition, Clinical Modification codes, as reported by Medi-
are and Medicaid Services for the years 1995 to 1998,
elf-reported history, and the use of selected drugs (22).
articipants with HF or missing data on HF at baseline
n  140) were excluded from this analysis. Of the 2,935
articipants without HF at baseline, 2,612 (89.0%) had
vailable IL-6, TNF-, and CRP serum concentrations.
wo participants were excluded because of extreme outlier
alues of TNF-; the remaining 2,610 participants were
ncluded in this study.
erum biomarker measurements. In the Health ABC
tudy, concentrations of biomarkers were obtained from
rozen stored serum or plasma collected at baseline after an
vernight fast. Samples were obtained in the morning, and
fter processing, the specimens were frozen at 70°C and
hipped to the Core Laboratory at the University of Ver-
ont. Cytokines were measured in duplicate by enzyme-
inked immunosorbent assay. The detectable limit for IL-6
as 0.10 pg/ml and 0.18 pg/ml for TNF-. Serum concen-
rations of CRP were also measured in duplicate by enzyme-
inked immunosorbent assay on the basis of purified protein
nd polyclonal anti-CRP antibodies. The CRP assay was
tandardized according to World Health Organization First
nternational Reference Standard with a sensitivity of 0.08
g/ml. Blind duplicate analyses (n  150) for IL-6, CRP,
nd TNF- showed interassay coefficients of variation of
0.3%, 8.0%, and 15.8%, respectively.
Repeat determinations of IL-6 and CRP serum levels at
he year 2 visit (i.e., at the first 1-year follow-up) were
vailable for 2,372 (90.9%) and 2,370 (90.8%) of the 2,610
articipants with inflammatory marker levels at baseline.
epeat determinations were not available for TNF-. The
ear 2 samples of IL-6 and CRP were analyzed in a different
aboratory (Wake Forest University) than the baseline
amples (University of Vermont) and calibrated based on
50 samples that were analyzed at both Wake Forest
niversity and University of Vermont. The intraclass cor-
elation coefficient for the calibrated samples was 0.93 for
L-6 and 0.89 for CRP.
tudy definitions. Race was self-defined by the partici-
ant. Hypertension was defined as self-reported history of
hysician diagnosis accompanied by use of antihypertensive
edications. Diabetes was defined as self-reported history
f diabetes or use of antidiabetes medications. Smoking
tatus was classified as current, past (100 lifetime ciga-
ettes), or never. Left ventricular hypertrophy was diagnosed
ased on an electrocardiogram using the following voltage
riteria: R amplitude 26 mm in either V5 or V6 or R
mplitude 20 mm in any of leads I, II, III, aVF, or R
mplitude12 mm in lead aVL or R amplitude in V5 or V6
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May 11, 2010:2129–37 Inflammatory Markers and Heart Failure Risklus S amplitude in V1 35 mm. Definite CHD was
efined as: 1) history of coronary artery bypass graft or
ercutaneous coronary angioplasty; 2) electrocardiographic
vidence of myocardial infarction; or 3) history of myocar-
ial infarction or angina accompanied by use of antianginal
edications. Probable CHD was defined as self-reported
istory of myocardial infarction or angina without the use of
ntianginal medications. Cerebrovascular disease was de-
ned as history of stroke, transient ischemic attack, or
arotid endarterectomy. Peripheral arterial disease was de-
ned as history of claudication or lower extremity bypass or
ngioplasty. Methods of assessment of the ankle-arm index
n the Health ABC Study were previously published (23).
tudy outcomes. All participants were asked to report any
ospitalizations and every 6 months were asked direct
uestions to elicit information about interim events. All first
dmissions with an overnight stay confirmed to be related to
F by local adjudicators were classified as incident HF.
djudication criteria for HF required, in addition to a
hysician diagnosis of HF: 1) medical record documenta-
ion of symptoms (e.g., shortness of breath, fatigue, orthop-
ea, paroxysmal nocturnal dyspnea) and physical signs (e.g.,
dema, pulmonary rales, gallop rhythm); 2) supporting
linical findings such as evidence of pulmonary edema on
hest radiography or evidence supporting HF on echocar-
iography; and 3) medical therapy for HF, including at least
diuretic and a vasodilator and/or digitalis. Information on
eft ventricular ejection fraction (EF) post-HF development
as abstracted from any imaging report in the medical
ecord. Incident CHD was defined as hospitalization for
yocardial infarction, angina pectoris, or elective coronary
evascularization, either surgical or percutaneous.
tatistical analysis. The proportion of variance of inflam-
atory markers explained by baseline characteristics was
ssessed by using multiple regression. The association of
nflammatory markers with HF risk was assessed with Cox
roportional hazards models. Inflammatory marker concentra-
ions were log transformed before regression analyses because
f skewed distributions. We opted for log2 transform (i.e.,
ogarithm with basis 2) to facilitate communication because the
azard ratio (HR) per log2-transformed increase denotes the
ncrease in hazard associated with doubling of the original
alue. The proportionality assumption in Cox models was
ssessed with the Schoenfeld residuals.
In multivariable models, we controlled for: 1) baseline
haracteristics, including use of antihypertensive and anti-
nflammatory medications (entered as a binary indicator
ariable for each class); and 2) the ankle-arm index, as a
easure of subclinical atherosclerosis, and time-varying
ncident CHD evaluated at 1-year intervals in nested
odels. We repeated these analyses in subgroups defined by
he presence or absence of any atherosclerotic disease
definite or probable CHD, cerebrovascular disease, or
eripheral arterial disease). Finally, we repeated these anal-
ses with death as a competing event, using the competing bisks model (proportional subhazards model) proposed by
ine and Gray (24).
In secondary analyses, we assessed the association be-
ween inflammatory markers and risk of HF with reduced
45%) versus preserved (45%) left ventricular EF. Al-
hough there is no universally accepted cutoff point for EF,
n EF 45% is considered to represent preserved systolic
unction by most investigators and has also been used in
ecent trials (25,26). For this analysis, only new HF cases
ith documented left ventricular EF were considered as
vents in separate (reduced vs. preserved) Cox models. In
ddition, we assessed the effect of combined elevations of
ultiple inflammatory markers on HF risk. For this analy-
is, we empirically divided biomarker values using the
ohort median. Finally, we evaluated the prognostic value of
hanges in IL-6 and CRP at 1-year follow-up for future
ncident HF among the 2,370 participants who had repeat
L-6 and CRP determinations and were still free of HF at
-year follow-up.
The incremental value of inflammatory markers for HF
isk prediction over the Health ABC HF model (14) was
ssessed with the Harrell’s C index for survival models and
he change in Bayes information criterion, a likelihood-
ased measure of model fit that penalizes for the number of
ariables in the model (27,28). For calculation of the Bayes
nformation criterion, we applied the Volinsky and Raftery
28) modification for censored data, and corresponding
values for improvement were calculated according to
agenmakers (29).
For multivariable models, missing values of covariates were
mputed using the multiple imputation by chained equations
rocedure (30,31). Parameter estimates were obtained by
ombining 5 imputed datasets using the method described by
arnard and Rubin (32) to account for possible error in missing
alue analysis. A 2-sided p  0.05 was accepted as statistically
ignificant for all analyses. Analyses were performed with
TATA versions 10 and 11 (StataCorp, College Station,
exas).
esults
aseline participant characteristics and inflammatory
arker distribution. Table 1 shows the baseline partici-
ant characteristics and Table 2 shows the distribution of
iomarkers overall and by HF development. The mean age
f participants was 73.6  2.9 years; 48.3% were men and
9.6% were white. During a median follow-up of 9.4 years
interquartile range [IQR] 7.0 to 9.4), HF developed in 311
11.9%) participants (15.1 cases per 1,000 person-years) and
90 participants (30.3%) died (3.7% annual mortality rate).
Table 3 presents the correlation between the inflamma-
ory markers and baseline participant characteristics. Mul-
iple statistically significant correlations were detected; how-
ver, these were modest. In multiple regression analyses,
aseline characteristics were able to explain 16.2%, 27.6%,
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Inflammatory Markers and Heart Failure Risk May 11, 2010:2129–37nd 16.2% of the variance of log-transformed IL-6, TNF-,
nd CRP, respectively.
nflammatory markers and incident HF. All inflamma-
ory markers were associated with HF risk in unadjusted
aseline Participant Characteristics (N  2,610)Table 1 Baseline Participant Characteristics (N  2,610)
Characteristic Value
Age, yrs 73.6 2.9
Male sex, % 48.3
Black race, % 40.4
Body mass index, kg/m2 27.3 4.7
Waist/thigh circumference ratio 1.95 0.21
Smoking, %
Current 10.5
Past 44.6
Alcohol consumption, %
Never 49.5
1 drink/week 21.5
1–7 drinks/week 21.9
7 drinks/week 7.0
Diabetes mellitus, % 14.8
Hypertension, % 53.1
Coronary heart disease, %
Definite 16.2
Probable 3.3
Cerebrovascular disease, % 7.7
Peripheral arterial disease, % 4.8
Left ventricular hypertrophy, % 12.1
Systolic blood pressure, mm Hg 136 21
Diastolic blood pressure, mm Hg 71 12
Heart rate, beats/min 65 11
Fasting glucose, mg/dl* 94 (87–105)
Albumin, g/dl 4.0 0.3
Creatinine, mg/dl* 1.0 (0.9–1.2)
Total cholesterol, mg/dl 203 38
Low-density lipoprotein, mg/dl 122 34
High-density lipoprotein, mg/dl 54 17
Triglycerides, mg/dl* 118 (88–161)
Medications, %
Beta-blockers 12.2
Angiotensin-converting enzyme inhibitors 14.3
Calcium channel blockers 22.2
Thiazide diuretics 17.6
Other antihypertensive 8.5
Statins 12.5
Steroids 2.2
Nonsteroidal anti-inflammatory agents† 51.4
Value expressed as median (interquartile range) because of highly skewed distributions. †Includ-
ng salicylates.
nflammatory Markers According to Incident HF DevelopmentTable 2 Inflammatory Markers According to Incident HF Develo
Marker
Total Cohort
(n  2,610)
Particip
Interleukin-6, pg/ml* 1.80 (1.23–2.76)
Tumor necrosis factor-, pg/ml* 3.14 (2.41–4.06)
C-reactive protein, g/ml* 1.64 (0.99–3.04)Values are expressed as median (interquartile range) because of highly skewed distributions and comp
HF  heart failure.nalyses; HR per doubling of levels was 1.61 (95% confi-
ence interval [CI]: 1.43 to 1.80; p  0.001) for IL-6, 1.83
95% CI: 1.51 to 2.21; p  0.001) for TNF-, and 1.25
95% CI: 1.14 to 1.36; p  0.001) for CRP. The propor-
ional hazards assumption was valid for all 3 markers
p value for the chi-square test of Schoenfeld residuals was
.55, 0.73, and 0.45, for IL-6, TNF-, and CRP, respec-
ively) and association with HF risk was similar across sex
nd race (p values for interaction terms 0.15). In models
ontrolling for all baseline characteristics, the association of
L-6 and TNF- with HF risk remained significant,
hereas that of CRP was attenuated (Table 4). Adding the
aseline ankle-arm index (as a measure of baseline subclin-
cal atherosclerosis) and incident CHD as a time-varying
ovariate in the model did not materially affect the esti-
ates; doubling of concentrations of IL-6, TNF-, and
RP was associated with 29% (95% CI: 13% to 47%), 46%
95% CI: 17% to 84%), and 9% (95% CI: 1% to 24%)
ncrease in HF risk, respectively, in fully adjusted models
Table 4). When all markers were entered simultaneously in
djusted models, only IL-6 and TNF-, but not CRP,
emained independently associated with HF risk.
In subgroups defined by the presence or absence of any
therosclerotic (CHD, cerebrovascular or peripheral) dis-
ase at baseline, IL-6 and TNF- were associated with
ncident HF risk in both subgroups. Notably, TNF-
eemed to be a stronger predictor of HF among participants
ith prevalent atherosclerotic disease, whereas IL-6 was a
tronger predictor among participants without atheroscle-
otic disease at baseline. Considering that this is a post hoc
nalysis based on a posteriori definition, these results need
o be interpreted with caution.
When death was accounted for as a competing event using
he Fine and Gray proportional subhazards models, IL-6 and
NF-were still strongly associated with incident HF risk and
oth provided complementary information in models with all
arkers included (Table 5), whereas CRP was not associated
ith incident HF in competing risks models.
ncident HF with preserved and reduced EF. Informa-
ion on post-HF left ventricular EF was available for 239
76.8%) of 311 incident HF cases. Median EF was 43%
IQR, 27% to 55%). When only cases with preserved EF
ere considered (105 of 239; 43.9%), IL-6 (HR per
oubling, 1.48; 95% CI: 1.19 to 1.86, p  0.001) and
NF- (HR per doubling, 1.81; 95% CI: 1.23 to 2.68, p 
.003) were strongly associated with HF risk in models
nt
ithout Incident HF
2,299)
Participants With Incident HF
(n  311) p Value
1.20–2.67) 2.31 (1.56–3.43) 0.001
2.40–3.96) 3.49 (2.58–4.76) 0.001
0.97–2.97) 1.94 (1.18–3.81) 0.001pme
ants W
(n 
1.75 (
3.10 (
1.60 (ared with the Mann-Whitney test.
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May 11, 2010:2129–37 Inflammatory Markers and Heart Failure Riskontrolling for baseline characteristics; association was less
obust for CRP (HR per doubling, 1.15; 95% CI: 0.96 to 1.36,
 0.12). When all 3 markers were included in the model,
L-6 (HR per doubling, 1.40; 95% CI: 1.09 to 1.80, p 
.008) and TNF- (HR per doubling, 1.60; 95% CI: 1.08 to
.38, p  0.020) were independently associated with HF risk,
hereas CRP was not (HR per doubling, 1.01; 95% CI: 0.84
o 1.22, p 0.42). The associations of IL-6 and TNF- with
ncident HF did not materially change in models additionally
ontrolling for the ankle-arm index at baseline and incident
HD as time-varying covariates (data not shown). When only
F cases with reduced EF (134 of 239; 56.1%) were consid-
red, inflammatory markers were marginally associated with
F risk; HR per doubling of levels was 1.21 (95% CI: 0.99 to
.48; p  0.067) for IL-6, 1.36 (95% CI: 0.96 to 1.93; p 
.081) for TNF-, and 1.09 (95% CI: 0.93 to 1.27; p 0.28)
or CRP in models controlling for baseline characteristics. This
ssociation was further attenuated in models that additionally
ontrolled for the ankle-arm index at baseline and incident
HD (data not shown).
ultiple inflammatory marker elevations and incident
F risk. Compared with participants who had concentra-
ions below the cohort median for all 3 biomarkers (n 
15), those with 1 (n  795), 2 (n  776), or 3 (n  524)
iomarkers elevated at baseline had an increased risk of HF in
nadjusted analyses (HR: 1.45, 95% CI: 0.97 to 2.17, p 
.074; HR: 2.37, 95% CI: 1.61 to 3.48, p  0.001; and HR:
orrelation Between Inflammatory Markers and Baseline CharacterTable 3 Correlation Between Inflammatory Markers and Baseli
Variable
IL
rho
Age 0.036
Sex (men  0, women  1) 0.061
Race (white  0, black  1) 0.098
Body mass index 0.167
Waist/thigh circumference ratio 0.107
Smoking (no  0, past  1, current  2) 0.128
Alcohol consumption (drinks/week) 0.046
Diabetes mellitus (no  0, yes  1) 0.121
Hypertension (no  0, yes  1) 0.099
Coronary heart disease (no  0, probable  1, definite  2) 0.114
Cerebrovascular disease (no  0, yes  1) 0.042
Peripheral vascular disease (no  0, yes  1) 0.090
Left ventricular hypertrophy (no  0, yes  1) 0.064
Systolic blood pressure 0.044
Diastolic blood pressure 0.029
Heart rate 0.152
Fasting glucose 0.139
Albumin 0.140
Creatinine 0.124
Total cholesterol 0.119
Low-density lipoprotein 0.068
High-density lipoprotein 0.168
Triglycerides 0.053
ll correlation (rho) values refer to Spearman nonparametric rank correlation coefficients.
CRP  C-reactive protein; IL  interleukin; TNF  tumor necrosis factor..20, 95% CI: 2.16 to 4.74, p 0.001, respectively; p for trend m0.001). The increased risk persisted for those with 2 or 3
iomarkers elevated in models adjusted for baseline character-
stics (HR: 1.26, 95% CI: 0.83 to 1.90, p  0.27; HR: 1.65,
5% CI: 1.10 to 2.47, p 0.014; and HR: 1.76, 95% CI: 1.14
o 2.70, p  0.010, for participants with 1, 2, or 3 biomarkers
levated, respectively; p for trend  0.003) (Fig. 1). These
esults did not change when the ankle-arm index and incident
HD were included in the model (data not shown).
erial biomarkers and incident HF risk. Among the
,370 participants who had repeat determinations of IL-6
nd CRP at year 2 and were still free of HF, the median
ncrease in IL-6 and CRP levels from year 1 was 0.30 pg/ml
IQR0.39 to 1.25 pg/ml) and 0.51 g/ml (IQR1.07 to
.08 g/ml), respectively. Repeat IL-6 and CRP levels were
till associated with future HF risk (HR per doubling, 1.21;
5% CI: 1.09 to 1.36, p  0.001 and 1.12; 95% CI: 1.03 to
.21, p 0.006, respectively). However, the change in IL-6
r CRP from baseline to 1-year follow-up was not associ-
ted with HF risk (both p values 0.5).
ncremental value for incident HF prediction. We pre-
iously developed an HF risk prediction model, the Health
BC HF model (14). Addition of all 3 inflammatory
arkers to this clinical model increased the C index from
.717 (95% CI: 0.686 to 0.747) to 0.737 (95% CI: 0.709 to
.765), p  0.001 for the comparison, and improved model
t as assessed with the Bayes information criterion (de-
reased by 10.9 U; p  0.004). The improvement was
aracteristics
TNF- CRP
p Value rho p Value rho p Value
0.064 0.082 0.001 0.059 0.003
0.002 0.068 0.001 0.142 0.001
0.001 0.125 0.001 0.161 0.001
0.001 0.077 0.001 0.244 0.001
0.001 0.163 0.001 0.019 0.33
0.001 0.031 0.12 0.070 0.001
0.020 0.004 0.84 0.043 0.029
0.001 0.075 0.001 0.089 0.001
0.001 0.070 0.001 0.104 0.001
0.001 0.138 0.001 0.011 0.57
0.032 0.032 0.10 0.028 0.15
0.001 0.068 0.001 0.053 0.007
0.001 0.023 0.25 0.028 0.15
0.026 0.010 0.62 0.039 0.049
0.14 0.025 0.20 0.003 0.87
0.001 0.031 0.11 0.145 0.001
0.001 0.093 0.001 0.088 0.001
0.001 0.038 0.05 0.101 0.001
0.001 0.274 0.001 0.017 0.37
0.001 0.025 0.19 0.052 0.008
0.001 0.012 0.54 0.155 0.43
0.001 0.304 0.001 0.002 0.93
0.007 0.309 0.001 0.097 0.001isticsne Ch
-6ainly due to IL-6; adding only IL-6 to clinical predictors
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 0.001 for the comparison), and improved the Bayes
nformation criterion by 17.8 U (p  0.001) because of a
ore parsimonious model.
iscussion
n this study, we validate earlier observations suggesting that
nflammatory cytokines are associated with incident HF
isk. In our study, IL-6 and TNF- were independently
ssociated with HF development, whereas CRP demon-
trated a weaker association. These findings were consistent
n both sexes and in blacks and whites and persisted in
odels controlling for clinical characteristics, the ankle-arm
nflammatory Biomarkers and Incident HF RiskTable 4 Infla matory Biomarkers and Incident HF Risk
Inflammatory Marker
All (N  2,610)
HR (95% CI) p Value
Individual markers: model 1*
Interleukin-6, per log2 1.32 (1.16–1.50) 0.001
Tumor necrosis factor-, per log2 1.49 (1.19–1.87) 0.001
C-reactive protein, per log2 1.11 (1.00–1.23) 0.051
Individual markers: model 2†
Interleukin-6, per log2 1.29 (1.13–1.47) 0.001
Tumor necrosis factor-, per log2 1.46 (1.17–1.84) 0.001
C-reactive protein, per log2 1.09 (0.99–1.21) 0.087
Pooled markers: model 1*
Interleukin-6, per log2 1.26 (1.09–1.46) 0.002
Tumor necrosis factor-, per log2 1.39 (1.10–1.74) 0.005
C-reactive protein, per log2 1.02 (0.91–1.14) 0.73
Joint significance 0.001
Pooled markers: model 2†
Interleukin-6, per log2 1.24 (1.07–1.44) 0.004
Tumor necrosis factor-, per log2 1.41 (1.12–1.77) 0.003
C-reactive protein, per log2 1.01 (0.90–1.13) 0.91
Joint significance 0.001
R expressed per log2 (logarithm with basis 2), equivalent to the HR per doubling of the original va
oronary heart disease, cerebrovascular disease, or peripheral arterial disease at baseline. *Mode
ariables plus ankle-arm index and time-varying incident coronary events.
CI  confidence interval; HR  hazard ratio; other abbreviation as in Table 2.
Inflammatory Biomarkers and Incident HF WithTable 5 Infla matory Biomarkers and Incide
Inflammatory Marker
M
sHR (95% C
Individual markers
Interleukin-6, per log2 1.23 (1.08–1.4
Tumor necrosis factor-, per log2 1.45 (1.15–1.8
C-reactive protein, per log2 1.07 (0.97–1.1
Pooled markers
Interleukin-6, per log2 1.19 (1.03–1.3
Tumor necrosis factor-, per log2 1.37 (1.09–1.7
C-reactive protein, per log2 1.01 (0.91–1.1
Joint significance
sHR expressed per log2 (logarithm with basis 2), equivalent to the sHR
baseline characteristics and medication use as described in Table 1. †
coronary events.
sHR  subhazard ratio; other abbreviations as in Tables 2 and 4.ndex, and incident coronary events. In addition, both IL-6
nd TNF- were associated with incident HF in models
ith death as a competing risk. The association between
nflammatory markers and HF risk was stronger for HF
ith preserved as opposed to reduced EF; this, however,
eeds cautious interpretation as post-HF EF was not
niformly assessed in the Health ABC Study. Finally, serial
eterminations of IL-6 and CRP added little information.
sing the clinical Health ABC HF model as baseline, we
ound that addition of IL-6 in the model improved model
erformance. These observations underscore the relation-
hip between inflammation and HF risk and may have
creening and prevention implications.
Atherosclerotic Disease at
Baseline (n  665)
No Atherosclerotic Disease at
Baseline (n  1,945)
HR (95% CI) p Value HR (95% CI) p Value
1.23 (1.02–1.48) 0.032 1.40 (1.18–1.66) 0.001
1.73 (1.26–2.38) 0.001 1.40 (1.06–1.84) 0.018
1.02 (0.88–1.17) 0.82 1.19 (1.05–1.36) 0.009
1.18 (0.98–1.42) 0.090 1.38 (1.17–1.64) 0.001
1.71 (1.25–2.35) 0.001 1.36 (1.04–1.82) 0.025
0.98 (0.85–1.14) 0.84 1.19 (1.04–1.35) 0.010
1.23 (0.99–1.52) 0.062 1.30 (1.07–1.58) 0.009
1.65 (1.20–2.27) 0.002 1.25 (0.94–1.66) 0.13
0.95 (0.81–1.11) 0.52 1.08 (0.94–1.25) 0.28
0.002 0.001
1.19 (0.96–1.48) 0.10 1.28 (1.06–1.56) 0.013
1.65 (1.20–2.27) 0.002 1.23 (0.92–1.63) 0.16
0.92 (0.78–1.08) 0.31 1.08 (0.93–1.25) 0.30
0.004 0.001
he parameter. Atherosclerotic disease at baseline was defined as presence of definite or probable
sted for baseline characteristics and medication use as described in Table 1. †Model 2: model 1
as a Competing RiskF With Death as a Competing Risk
* Model 2†
p Value sHR (95% CI) p Value
0.002 1.21 (1.06–1.38) 0.005
0.001 1.43 (1.13–1.80) 0.002
0.17 1.06 (0.96–1.17) 0.26
0.020 1.17 (1.01–1.35) 0.037
0.008 1.39 (1.07–1.72) 0.011
0.88 1.00 (0.90–1.11) 0.99
0.001 0.003
ubling of the original value of the parameter. *Model 1: adjusted for
2: model 1 variables plus ankle-arm index and time-varying incidentlue of t
l 1: adjuDeathnt H
odel 1
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May 11, 2010:2129–37 Inflammatory Markers and Heart Failure RiskThe rate of incident HF in our study was similar to that
n a recent cohort study reporting on HF incidence among
lder adults (33). Importantly, these rates are lower com-
ared with administrative data (34,35). Varying rates of
ncident HF have also been reported by the Framingham
eart Study and the Cardiovascular Health Study and from
lmsted County, Minnesota (36–38). These differences are
ikely related to different age, racial mix, geographic varia-
ion, and so forth, but also to varying diagnostic criteria.
egardless of the precise estimate, a high incidence rate,
orsening profile with aging, and either stagnant or increas-
ng incidence rates over the past decades are common
ndings across these studies.
Inflammation may contribute to HF development in
ultiple ways. An enhanced inflammatory state may create
milieu that increases the risk of HF because many HF risk
actors are associated with inflammation. Indeed, in our
nalysis, all risk factors for HF in the Health ABC cohort
14), albeit modestly, were correlated with inflammatory
arker levels. However, our data suggest that inflammation
ay also have a more direct role in HF development because
he association between inflammation and HF persisted
espite controlling for known HF risk factors. Previous data
upport our findings. The Framingham investigators
howed that there was a 60% (with TNF-) to 68% (with
L-6) increase in HF risk per tertile increase in cytokine
oncentration (11). Two other studies suggested a similar
ssociation (12,13); however, all 3 studies had a small
umber of HF cases (n  100). In this respect, the large
umber of incident HF cases and the longer follow-up in
ur study (median, 9.4 years) allowed us to control for
ultiple risk factors and incident CHD and perform im-
ortant subgroup analyses.
Previous reports support a potential direct role for inflam-
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Figure 1 HF Rates According to the Number of
Elevated Inflammatory Markers at Baseline
Adjusted Kaplan-Meier plots illustrating cumulative heart failure (HR) incidence
among Health ABC Study participants according to the number of elevated
inflammatory markers (interleukin-6, tumor necrosis factor-, and C-reactive
protein) at baseline. Adjustment model included all baseline characteristics as
described in Table 1.ation in HF development. Both IL-6 and TNF- affect tardiomyocyte contractility (39–41). These cytokines also
nfluence left ventricular remodeling and hypertrophy
42–45). Interestingly, unlike the previous studies (11–13),
RP levels had a weak association with HF risk in our study
nd were not associated with HF in models including IL-6
nd TNF-. This is likely related to the rigorous controlling
or confounders in our study. Although CRP may promote
eft ventricular remodeling by stimulating IL-6 production
46), there are no data to suggest a direct association
etween CRP levels and left ventricular remodeling. More-
ver, elevated CRP levels may reflect increased hepatic
ynthesis under the influence of elevated IL-6 levels and
hus represent a “distal” phenomenon secondary to a more
proximal” primary excess production of IL-6 (47,48).
Several additional observations from our study merit
ttention. First, our findings were consistent across sex and
n white and black participants. Second, inflammatory
arker levels had a strong association with HF with
reserved EF. This association is plausible because inflamma-
ion has been linked with diastolic dysfunction in patients with
ypertension (49) and CHD (8,9), and inhibition of inflam-
atory pathways prevents diastolic dysfunction in experimen-
al diabetic cardiomyopathy (50,51). This finding has impor-
ant implications because HF is primarily a disease of the
lderly, and HF develops in many of these individuals with
reserved EF. However, cautious interpretation is needed
ecause post-HF left ventricular function was not systemati-
ally assessed in the Health ABC Study and the corresponding
ndings are therefore subject to possible selection bias.
What are the implications of these findings? First, it
rovides pathophysiological insights into HF development
nd raises the possibility that inflammation might be a
arget for prevention interventions in selected individuals.
or example, agents with anti-inflammatory properties
e.g., statins) might be able to modulate HF risk among
ndividuals with elevated levels of inflammatory biomarkers
ho are at high risk of the development of HF. If proven,
his might be especially important for HF with preserved
F, for which no effective therapy currently exists. Indeed,
n the statin trials for secondary prevention, incident HF
eduction was reported (52,53), and statins have been shown
o prevent ventricular remodeling in experimental studies
54,55). However, whether targeted administration of st-
tins would attenuate HF risk among high-risk individuals
s speculative and needs further study. In addition, if IL-6
ssays were to be developed and commercially available, it is
ossible that adding IL-6 to clinical predictors might
acilitate earlier identification of high-risk individuals and
mplementation of preventive strategies.
tudy limitations. Our study has several limitations. Di-
gnosis of HF was based on HF hospitalization. Because
F may have developed in some participants without
equiring hospitalization, HF rates are likely underesti-
ated. Echocardiography was not performed at baseline in
he Health ABC Study, and thus participants with asymp-
omatic structural heart abnormalities may have been in-
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Inflammatory Markers and Heart Failure Risk May 11, 2010:2129–37luded in the analysis. It may be argued, therefore, that the
isk associated with elevated inflammatory marker levels is
erely because of inclusion of participants with yet unde-
ected HF at baseline. However, the association with HF
isk was consistent over time, as shown by the proportion-
lity tests (i.e., hazards did not converge over time). Because
F is unlikely to remain undiagnosed for several years, we
ontend that the observed association cannot be ascribed
erely to undetected HF at baseline. Also, left ventricular
unction during hospitalization for HF was not prospec-
ively assessed in the Health ABC Study, and information
n left ventricular EF was based on chart review in a subset
76.8%) of participants with incident HF; thus, the corre-
ponding results should be interpreted with caution.
onclusions
n this study, we demonstrate a significant association
etween inflammatory markers and risk of incident HF
mong older persons. These findings were consistent across
ex and race and persisted after controlling for HF risk
actors and incident CHD. Multiple biomarker elevations at
aseline were associated with a pronounced risk of HF.
nclusion of IL-6 in a clinical model for HF risk prediction
ignificantly improved the predictive properties of the
odel. The practical implications of our findings, including
creening individuals for HF risk determination and target-
ng inflammation to reduce HF risk, need further study.
eprint requests and correspondence: Dr. Javed Butler, Cardi-
logy Division, Emory University Hospital, 1365 Clifton Road
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